Finanzen von Dianthus Therapeutics Inc (DNTH)DNTHDianthus Therapeutics Inc

Evaluating the bottom line, Dianthus Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8079.11%, while the net margin is -6598.55%. These profitability ratios, combined with a Return on Equity (ROE) of -26.07%, provide a clear picture of how effectively DNTH converts its operational activities into shareholder value.

In the context of the broader market, DNTH competes directly with industry leaders such as COGT and CRSP. With a market capitalization of $5.91B, it holds a significant position in the sector. When comparing efficiency, DNTH's gross margin of 100.00% stands against COGT's N/A and CRSP's 100.00%. Such benchmarking helps identify whether Dianthus Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Dianthus has a gross margin of 100%, but it has been struggling with net income losses, reporting -$50,215,000 in Q2 2026. The current ratio is very strong at 26.10, indicating good liquidity.